Ceyla ERALDEMİR, Esra TERZİ DEMİRSOY, Elif BİRTAŞ ATEŞOĞLU, Özgür Doğa ÖZSOY, Abdullah HACIHANEFİOĞLU, Ayfer GEDÜK, Özgür MEHTAP, Pınar TARKUN, Canan ALBAYRAK

The role of hepcidin, GDF15, and mitoferrin-1 in iron metabolism of polycythemia vera and essential thrombocytosis patients

Background/aim: GDF15, hepcidin and mitoferrin-1 (mfrn-1) are proteins involved in systemic iron regulation. There are no studiesin the literature demonstrating the serum mfrn-1 levels in polycythemia vera (PV) and essential thrombocythemia (ET) patients. Theaim of this study was to investigate GDF15, hepcidin and mfrn-1 levels in PV and ET patients.Materials and methods: Ten PV, 17 ET patients, and 27 healthy controls (HCs) were enrolled. GDF15, hepcidin and mfrn-1 values weremeasured with enzyme-linked immunosorbent assay (ELISA).Results: GDF15 levels were higher in the myeloproliferative neoplasm (MPN) group (P = 0.002). Hepcidin levels were not differentbetween MPN patients and HCs. The mfrn-1 levels were lower in MPN patients (P = 0.039). Hepcidin, GDF15, and mfrn-1 levels werenot different between PV and ET patients. mfrn-1 levels were lower in ET patients than HCs (P = 0.038).Conclusion: Increased erythropoiesis in MPNs may lead to high GDF15 levels in these patients. However, hepcidin was not suppresseddespite the increased GDF15 levels and erythropoiesis in these patients. Decrease in mfrn-1 in MPNs can be the result of its increasedturnover due to increased myelopoiesis. It can be hypothesized that similar hepcidin levels in patients and controls and low mfrn-1levels in patients may be a defense mechanism against erythroid activity and thromboembolic complications.

PDF

___

1. Hoffman R, Baker KR, Prchal JT. The polycythemias. In: Hoffman R, Benz EJ, Shattil SJ, editors. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA, USA: Saunders, Elsevier; 2005. pp. 1209-1291.
2. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011; 29: 573-582.
3. Tefferi A. JAK and MPL mutations in myeloid malignancies. Leukemia Lymphoma 2008; 49: 388-397.
4. Tefferi A. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J 2007; 13: 366-371.
5. Josef T, Prchal FJ. Polycythemia vera. In: Lichtman M, Kaushansky K, Beutler E, Seligsohn U, Kipps T, Prchal FJ, editors. Williams Hematology. 8th ed. New York, NY, USA: McGraw-Hill; 2010. pp. 1919-1943.
6. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009; 122: 78-86.
7. Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol 2010; 17: 184-90.
8. Nancy CA. ABCs of erythroid mitochondrial iron uptake. P Natl Acad Sci USA 2009; 106: 16012-16013.
9. Shaw GC, Cope JJ, Li L, Corson K, Hersey C, Ackermann GE, Gwynn B, Lambert AJ, Wingert RA, Traver D et al. Mitoferrin is essential for erythroid iron assimilation. Nature 2006; 440: 96-100.
10. Paradkar PN, Zumbrennen KB, Paw BH, Ward DM, Kaplan J. Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2. Mol Cell Biol 2009; 29: 1007-1016.
11. Chen W, Paradkar PN, Li L, Pierce EL, Langer NB, TakahashiMakise N, Hyde BB, Shirihai OS, Ward DM, Kaplan J et al. Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria. P Natl Acad Sci USA 2009; 106: 16263-16268.
12. Chen W, Dailey HA, Paw BH. Ferro chelatase forms an oligomeric complex with mitoferrin-1 and Abcb10 for erythroid heme biosynthesis. Blood 2010; 116: 628-630.
13. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810.
14. Winder A, Lefkowitz R, Ghoti H, Leiba M, Ganz T, Nemeth E, Rachmilewitz EA. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol 2008; 142: 668-680.
15. Kwapisz J, Zekanowska E, Jasiniewska J. Decreased serum prohepcidin concentration in patients with polycythemia vera. J Zhejiang Univ Sci B 2009; 10: 791-795.
16. Frazer DM, Anderson GJ. Hepcidin compared with prohepcidin: an absorbing story. Am J Clin Nutr 2009; 89: 475- 476.
17. Tarkun P, Mehtap Ö, Ateşoğlu EB, Gedük A, Musul MM, Hacıhanefioğlu A. Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia. Eur J Haematol 2013; 91: 228-235.
18. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096-1101.
19. Tamary H, Shalev H, Perez-Avraham G, Zoldan M, Levi I, Swinkels DW, Tanno T, Miller JL. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 2008; 112: 5241-5244.
20. Musallam KM, Taher AT, Duca L, Cesaretti C, Halawi R, Cappellini MD. Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion independent patients with b thalassemia intermedia. Blood Cells Mol Dis 2011; 47: 232-234.
21. Mast AE, Foster TM, Pinder HL, Beczkiewicz CA, Bellissimo DB, Murphy AT, Kovacevic S, Wroblewski VJ, Witcher DR . Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion 2008; 48: 2197-2204.
22. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol 2008; 15: 169-175.
23. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN. JAK2 associates with the erythropoietin receptor and is tyrosinephosphorylated and activated followings simulation with erythropoietin. Cell 1993; 74: 227-236.
24. Domenico ID, Lo E, Ward DM, Kaplan J. Hepcidin-induced internalization of ferroportin re- quires binding and cooperative interactions with Jak2. P Natl Acad Sci USA 2009; 106: 3800-3805.
25. Ross SL, Tran L, Winters A, Lee KJ, Plewa C, Foltz I, King C, Miranda LP, Allen J, Beckman H et al. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell Metab 2012; 15: 905-917.